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Abstract
Background: It is well known that cancer cells bypass the restriction point, R, and undergo
uncontrolled cell proliferation.
Hypothesis and evidence: We suggest here that fibrosarcoma cells enter G1ps directly from M,
skipping G1pm, hence bypassing R, in response to redox modulation. Evidence is presented from the
published literature that demonstrate a shortening of the cycle period of transformed fibroblasts
(SV-3T3) compared to the nontransformed 3T3 fibroblasts, corresponding to the duration of G1pm
in the 3T3 fibroblasts. Evidence is also presented that demonstrate that redox modulation can
induce the CUA-4 fibroblasts to bypass R, resulting in a cycle period closely corresponding to the
cycle period of fibrosarcoma cells (HT1080).
Conclusion: The evidence supports our hypothesis that a low internal redox potential can cause
fibrosarcoma cells to skip the G1pm phase of the cell cycle.
Background
The normal cell cycle consists of four main phases; G1, S,
G2 and M. G1 is further subdivided into two parts, G1pm
and G1ps [1]. In G1pm, a series of mitogenic events prepares
the cell to enter G1ps and to continue to S and M [1,2]. At
the end of G1pm, there is a restriction point, R, which mon-
itors the cell and checks its qualifications for entry into
G1ps. If the accumulation of mitogenic events is inade-
quate, or if the cell is confluent with neighboring cells
fully around its perimeter, the cell cannot pass from G1pm
through R into G1ps and proliferate. Instead, the cell leaves
the cell cycle and enters G0, the quiescent phase [1-5].
Cancer cells, on the other hand, bypass R with consequent
uncontrolled proliferation [2].
Zetterberg and Larsson demonstrate that the transformed
3T3 cells, SV-3T3, behave in a similar way [3,4]. Further-
more, they demonstrate that these transformed cells do
not enter G0. They conclude from this that tumor cells do
not enter G0 [4].
Zetterberg and Larsson [1] have measured the duration of
both G1pm and the complete cell cycle. Larsson and Zetter-
berg [3] have determined the cycle period of SV-3T3 cells.
From the data in [1] and [3], we calculate that the differ-
ence between the cycle periods of the 3T3 and SV-3T3 cells
is 23%; i.e. the cycle period of SV-3T3 cells is 23% shorter
than that of 3T3 cells and matches the duration of G1pm.
We hypothesize here that the 23% decrease in cycle period
of SV-3T3 is observed because these cells skip G1pm and
enter G1ps directly from the exit from M. In skipping G1pm
the SV-3T3 cells bypass R. This hypothesis is supported by
the following: (1) it readily accounts for the qualitative
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differences between non-transformed and transformed
cells as noted above; and (2) it accounts for the quantita-
tive difference between the non-transformed and trans-
formed cell-cycle periods.
The relationship between Rb brake and other aspects of
cell cycle is depicted in figure 1. The mechanism we sug-
gest for the cancer cell skipping G1pm follows from our
model of redox modulation of cellular proliferation [6].
Beyond the restriction point, R, the cell is committed to
duplicating its DNA and proceeding to mitosis. For a cell
to pass R, special proliferation-promoting proteins must
be phosphorylated to promote the activation of the genes
necessary for the cell to traverse R, enter G1ps, and prolif-
erate. These include the retinoblastoma protein (pRb)
[2,5], regulatory enzymes such casein kinase [7], and tran-
scription factors such as jun [7] and NF-κB [8]. When the
intracellular redox potential, E, is high, these proteins are
dephosphorylated; when E is low they are phosphorylated
[7-10].
An example of a critical phosphorylation-dependent path-
way regulating passage through G1pm is the cyclin D-cdk4
complex. This complex phosphorylates pRb, thereby
deactivating its repressor activity and allowing for tran-
scription of S-phase genes. For this reason, the hypothesis
is limited to transformed and malignant cells in which
pRb is functional. According to the redox model, the
dephosphorylation of pRb can occur only if the intracel-
lular redox potential, E, is above a threshold value, θ,
which we have estimated to be between -218 and 196 mV
[6]. The cell normally sets E below θ when the activating
proteins are to be phosphorylated, and sets E  above θ
when they are to be dephosphorylated [6] (see figure 1).
During normal proliferation, when the cell is in M, a
phosphatase dephosphorylates pRb [5], and the transcrip-
tion factors no longer become available for activating the
proliferation-promoting genes. The cell then exits M and
enters G1pm and again begins to accumulate mitogenic
events necessary for the cell once more to pass R and enter
G1ps [2].
Relationship between Rb brake and other aspects of cell cycle Figure 1
Relationship between Rb brake and other aspects of cell cycle. The Rb protein acts as a brake on several of the phases 
of the cell cycle, dependent upon its state of phosphorylation. In the hyperphosphorylated state, the Rb brake is inactive, per-
mitting the transcription factors to become activated and cellular proliferation to proceed. During this period the ratio 
[GSSG]/[GSH] is low and E falls below θ. The cell passes through the restriction point R to the later stage of G1, termed G1ps, 
on to S, from which it passes through G2 to the early M phase. After mid-M, the Rb protein becomes hypophosphylated and 
the brake is active. The transcription factors are inactivated and cell proliferation is stopped. During this period the ratio 
[GSSG]/[GSH] is high and E rises above θ. The cell passes through M to the early stage of G1, termed G1pm, from which it may 
either return to the cell cycle via R or it passes into a resting stage, G0. In cancer, a portion of the cycle can be short-circuited, 
via the M to G1ps bypass. R = site of restriction point. Arrow with interrupted line represents short-circuit in cancer. θ = -207 
± 11 mV.Theoretical Biology and Medical Modelling 2006, 3:26 http://www.tbiomed.com/content/3/1/26
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Although multiple, often overlapping, pathways impinge
on cell-cycle regulatory points, pRb is one of the key
downstream elements known to play a critical regulatory
role [2,5]. Since the proper functioning of the unmutated
pRb is dependent on cycling between its phosphorylated
and unphosphorylated states, the redox state may contrib-
ute to altering the cell cycle by affecting pRb directly or at
an upstream point. According to this redox model, if E
were to be below θ for the duration of the complete cell
cycle, pRb would remain phosphorylated through the
cycle thereby resulting in loss of its normal regulatory
properties. Indeed, several workers have noted that the
level of phosphorylated pRb is higher in cancer than in
normal cells [11,12]. Our hypothesis is that some trans-
formed and malignant cells are characterized by an E that
is constantly below θ, regardless of external conditions
such as confluence or growth factors. A low E keeps pRb
from becoming dephosphorylated, preventing the pas-
sage from M into G1pm, but allowing their entry from M
directly into G1ps [5], resulting in these cells skipping
G1pm. Hutter et al. have reported that, in contrast to nor-
mal cells, the average E of fibrosarcoma cells is below the
value we have estimated as θ, independent of the degree
of confluence [13]. These cells can be thought of as inter-
nally redox-biased.
The redox model predicts that even normal cells, in which
E is artificially maintained below θ for a complete cell
cycle, will also skip, or short-circuit, G1pm. In other words,
the cycle period of an artificially redox-biased normal cell
will, according to the model, be shortened like the cycle
period of a cancer cell. As a result of the shorter cycle
period, the cell density of the redox-biased cells should be
higher than that of the non-redox-biased cells. Hutter et al.
[13] did exactly that experiment. They lowered E for 24
hours by adding GSH precursors. They did two experi-
ments, adding 0.05 mM N-acetylcysteine (NAC) in the
first and 0.002 mM oxothiazolidine-4-carboxylate in the
second. These additions each resulted in a lowering of E,
by 10 mV in the first and by 8 mV in the second. In both
cases, the resulting E was below our estimated value of θ
and in both cases the cell density increased by 26%, com-
pared to the controls, during the 24-hour experiment.
These data may be interpreted as the results of a combina-
tion of increased growth rate along with decreased sensi-
tivity to contact inhibition. To the extent that the cells are
not contact-inhibited, we can infer that they bypass R.
Results and discussion
The doubling time, τn, of various fibroblasts was meas-
ured, as was the doubling time of fibrosarcoma cells, τc
(see Table 1). Whereas doubling times can be dependent
on the passage level in the case of non-immortal cell lines,
as well as the culture medium, doubling times of normal
cells were determined only at low passage and represent
the lowest doubling times observed. Under these condi-
tions it is reasonable to suppose that the observed dou-
bling times of the fibroblasts were indeed representative
of the true doubling times and did not reflect the trapping
of some cells in G0. Table 1 shows the observed doubling
time for the fibrosarcoma cells as 18.2 h and that of the
CUA-4 fibroblasts as 24.1 h. Note that cancer cells do not
usually enter G0, so all cells contribute to the proliferation
and hence to the doubling time.
From Table 1, the ratio of the doubling time of the fibro-
sarcoma cells to that of the CUA-4 fibroblasts is
τc/τn = 18.2/24.1 = 0.76
Now let us calculate the doubling time of the CUA-4
fibroblasts (τn) and that of he externally redox-modulated
CUA-4 fibroblasts (τe) from the cell-density data of Hutter
et al. Since these latter cells do not enter G0 and do not
exhibit contact inhibition, their observed doubling time is
a measure of their cycle period.
For exponentially growing cells, it can be shown that the
ratio, r, of the cell densities of the redox-biased fibroblasts
compared to the non-redox-biased fibroblast controls is
given by
In the experiment of Hutter et al., the cell density of the E-
biased fibroblasts was 26% greater than that of the unbi-
ased cells, so we set r = 1.26 in (1). The duration of their
experiment was T = 24 h. As noted above, τn for CUA-4
cells = 24.1 h. We then deduce from (1) that τe = 18.1 h.
The ratio of the doubling time of the E-biased fibroblasts
to that of the unbiased fibroblasts is
τc/τn = 18.1/24.1 = 0.75
which compares favorably with the ratio computed above
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Table 1: Doubling Times of Fibroblasts and Fibrosarcoma cells‡





‡ Doubling times were determined from cell growth curves of 
duplicate cultures. Cell counts were made every 24 h over a period of 
96 h and the standard error in the counts was <2.5% for all curves. 
Normal fibroblast cultures were between passage levels of 9 to 20 
passages. HT1080 passage levels were in excess of 100 passages.Theoretical Biology and Medical Modelling 2006, 3:26 http://www.tbiomed.com/content/3/1/26
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Moreover, using the data from (1), we have computed the
doubling time of the 3T3 cells to be 15.40 h and that of
the cells if they had skipped G1pm to be 11.82 h. The ratio
of these is
The close correspondence of all three of these ratios sup-
ports our hypothesis that cells in which E is continually
below θ skip G1pm.
Although these numbers do not necessarily prove that E-
biased normal cells skip G1pm, they do show that their
doubling time is the same as that of fibrosarcoma cells. This
result may be consistent with these cells bypassing R by
skipping G1pm. Yet it is possible that the doubling time is
shorter only because none of the cells can now enter G0,
whereas without the E bias, some of the cells can enter G0.
This possibility seems unlikely, however, because of the
way the doubling times were measured. In any case, these
data do demonstrate a redox-mediated bypass of R that
reduces the doubling time of the normal cells to about 75%
of its former value. Data of the sort obtained by Zetterberg
& Larsson [1] for these CUA-4 cells and for the fibrosar-
coma cells would help determine how closely the cycle
period of normal cells corresponds to what would be the
period if the normal cell would have skipped G1pm.
Nevertheless, there are other types of transformed cells
that apparently behave differently. For example, Irani et al.
note that 3T3 cells transformed with H-ras V12 produce
superoxide constitutively, and such production is
required for their uncontrolled proliferation [14]. Expo-
sure of these cells to a reductant such as NAC inhibits their
growth. In contrast, these authors report in an earlier
paper that there is little if any response of Raf-transformed
3T3 cells to NAC [15]. Finkel reconciles these results [16]
by suggesting that in some cells, ROS may mediate growth
regulatory pathways, whereas in other cells, the data sug-
gest that ROS play a role in apoptotic pathways. Further-
more, other data may appear to be inconsistent with our
proposal of how E affects cell proliferation. For example,
Szatrowski and Nathan report that ROS production is
increased in cancer cells [17]. Radisky et al. report that
experimental evidence indicates a direct link between
abnormal signal transduction by oxygen species, that is
redox signaling, and malignant invasive cell growth [18].
In addition, Chiarugi and Cirri point out that transduc-
tion by ROS, through reversible phosphotyrosine phos-
phate, is triggered by growth-factor receptors [19].
Nevertheless, none of these results show that the increase
in ROS levels is sufficient to affect E significantly, nor do
they contradict the hypothesis of bypassing G1pm. Indeed,
attempts to measure the effect of increased physiological
concentrations of ROS have been shown to be inadequate
to alter cellular E [20] as defined here, and as seen by the
molecules in the cell. The addition of NAC to a cell does
not always alter the [GSSG]/[GSH] ratio (21). Martindale
and Holbrook [22] conclude that at the cellular level, the
response of cells to oxidants can range from proliferation,
to growth arrest, to senescence, and to cell death. The par-
ticular response varies from one type of cell to the next,
the agent, its dosage and duration of treatment [23].
Conclusion
In summary, we have presented two independent sets of
experimental data that are consistent with the difference
between the cell-cycle period of fibroblasts and trans-
formed SV-3T3 cells approximating the G1pm fraction of
the cycle period of the fibroblast controls, as measured by
Zetterberg and Larsson [1]. Moreover, the data demon-
strate that by imposing an external E bias on the fibrob-
lasts, they can be made to mimic the fibrosarcoma cell-
cycle period and its bypassing of R. These data support our
hypothesis that a low E can cause the fibrosarcoma cells to
skip G1pm.
This hypothesis has therapeutic ramifications. Larsson et
al. have suggested that further insight into the differences
between normal and transformed cells could be useful in
the search for anti-tumor agents [3]. Our hypothesis leads
to the conclusion that increasing the E of the some tumor
cells will not only prevent their skipping G1pm, but may
result in these cells being arrested in G1pm, and selectively
undergoing apoptosis [6]. An experiment that would par-
tially test our theory would be to raise the E of proliferat-
ing fibroblasts gradually by adding a GSH-decreasing
agent, such as diamide plus BCNU [23]. We predict that
cell proliferation would be unaffected as E rises, but when
E exceeds the value we have identified as the threshold,
proliferation will come to a stop. Such a response could be
exploited to provide a new treatment modality for some
forms of cancer.
Methods
The doubling times of tumor cells were measured and
compared to those of proliferating normal cells. Doubling
times were determined for cultures grown in Delbecco's
modified minimal essential medium supplemented with
10% fetal bovine serum. This formulation was deter-
mined to provide the shortest doubling times for the cells
studied. Although doubling times of these cell strains are
dependent upon passage level (for fibroblasts) and the
growth media used, including the brand and lot of serum,
this formulation provided fairly consistent results across
experiments and passage levels while retaining the relative
difference between the normal cell strains and the fibrosa-
rcoma cells. The doubling time was calculated from
growth curves. For this determination, each of the cell
doubling time of skipped T
T doubling time
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lines was inoculated into wells of a 24-well titer plate at a
density of 4 × 104 cells/well. The normal CU-4, GM08086,
and JHU-1 cells were at low passage levels (population
doubling 9 – 20). The CUA-4 and JHU-1 cells were
derived from primary cultures of human normal foreskins
at Catholic University of America, Washington, DC and
the Johns Hopkins University, respectively. The normal
fibroblasts GM08086 cell strain was obtained from the
Coriell Institute, Camden NJ, while the HT1080 fibrosar-
coma cells were obtained from American Type Culture
Collection (ATCC, Manassas, VA, USA). The passage num-
bers for HT1080 cells at the time of the experiment was
≥100 passages. A periodic determination of doubling
times for HT1080 remained fairly constant regardless of
passage level. Doubling times for CUA-4 and JHU cultures
were routinely measured in duplicate or triplicate and
showed little change up to about passage level 25 after
which doubling times became progressively longer, con-
sistent with in vitro senescence.
Cell counts were measured in duplicate in a hemocytom-
eter every 24 h for 96 h. The counts were plotted on a log
scale and were fitted to a straight line by linear regression.
The standard error in the counts with respect to the line of
regression was less than 2.5% for all curves. The correla-
tion coefficients of all the growth lines were in the range
0.91–0.93.
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GSH = reduced glutathione, GSSG = oxidized glutathione,
NAC = N-acetylcysteine, pRb = retinoblastoma protein,
ROS = reactive oxygen species
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